KAHR Bio Highlights Phase 2 Success for DSP107
Recent Phase 2 results have revealed a remarkable median overall survival of 17.5 months for patients battling advanced, chemo-refractory colorectal cancer.
With the closing of a $22 million financing, KAHR Bio is now poised to advance its Phase 2b trial, following the clearance of its investigational new drug application.
KAHR Bio (NASDAQ: KAHR), a pioneering clinical-stage biotechnology company, has unveiled its topline results from the Phase 2a expansion cohort evaluating DSP107, a groundbreaking bispecific T-cell engager, in combination with atezolizumab, an anti-PD-L1 antibody therapy. This combination has shown promising safety and clinical efficacy, particularly in patients with liver metastases, addressing a significant medical need in this patient population.
The company successfully closed a funding round to support a randomized Phase 2b trial of DSP107 in conjunction with atezolizumab against a currently available therapy for fourth-line metastatic microsatellite stable colorectal cancer (MSS-CRC). This trial, which commenced following FDA approval, focuses on a population that historically has low response rates to immunotherapy, with approximately 75% of trial participants having liver metastases.
The Phase 2a data demonstrated that DSP107 provides a median overall survival of 17.5 months, a notable improvement over established therapies which have reported survival rates between 6.4 and 10.8 months. With over 130 patients treated across various tumor types, DSP107 continues to exhibit a favorable safety and tolerability profile.
In this new Phase 2b trial, KAHR Bio aims to recruit patients through 18 sites in both Australia and the United States, which reflects the company’s robust expansion strategy. The drug has been specifically designed to activate T-cells by targeting the CD47 on cancer cells, creating a powerful immune response that is particularly needed in this difficult-to-treat patient group.
Dr. Anwaar Saeed, a leading oncologist involved in the trial, emphasized the unexpected efficacy of an immunotherapy approach in late-stage MSS-CRC with liver metastases. The mechanism of action of DSP107 cleverly utilizes overexpressed CD47 in these cancer cells, thus opening a unique therapeutic window.
Yaron Pereg, CEO of KAHR Bio, expressed optimism regarding the ongoing clinical trials and the supportive backing from investors. This backing not only signifies confidence in DSP107's clinical potential but also in KAHR Bio's strategic trajectory to meet significant medical needs in colorectal cancer treatment.
More About DSP107
DSP107 is KAHR Bio's flagship candidate, designed as a dual-targeting agent that aims to engage both the innate and adaptive immune systems. By selectively binding to CD47 on tumor cells, DSP107 overcomes previous safety hurdles faced by other therapies, effectively activating an immune response against tumors.
This innovative approach is particularly crucial in colorectal cancer, where most metastatic patients develop liver metastases that often resist standard therapies. DSP107 strives to transform a typically immunosuppressive tumor environment into one that is favorable for immune engagement, thereby enhancing anti-tumor responses.
Understanding Colorectal Cancer
Colorectal cancer remains one of the most widespread types of cancer globally, ranking high among both incidence and mortality. Approximately 85-90% of cases are classified as MSS, characterized by limited mutational burden and minimal immune activation. Current therapies have seen limited successes, leaving substantial unmet needs for more effective treatment options, making the ongoing research in immunotherapy both timely and vital.
About KAHR Bio
KAHR Bio is dedicated to developing innovative fusion protein therapeutics that stimulate immune responses against cancer while minimizing side effects. As they continue to evolve, the company is committed to transforming cancer treatment by focusing on dual-targeting agents. For further information about KAHR Bio, visit our official website.
Frequently Asked Questions
What were the key results of phase 2 trials for DSP107?
The Phase 2 trial showed a median overall survival of 17.5 months for patients with advanced colorectal cancer, surpassing existing therapies.
What is the significance of the $22 million financing?
This funding supports the ongoing development and clinical trials for DSP107, particularly the Phase 2b trial aimed at improving outcomes in colorectal cancer.
How does DSP107 work?
DSP107 works by targeting CD47 on cancer cells to activate T-cells, facilitating an immune response against tumors, notably in liver metastases.
What makes MSS-CRC challenging to treat?
MSS-CRC is often unresponsive to conventional immunotherapies due to low immune activation, making new approaches crucial.
What is KAHR Bio's focus moving forward?
KAHR Bio is concentrating on advancing DSP107 through clinical trials to realize its potential in treating colorectal cancer and addressing unmet medical needs.
